ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

By afschroeder • July 10, 2026

Assan F, Tragin M, Marella S, Lipecka J, Roger K, Zarhrate M, Bondet V, Nguyen V, Akroun F, Nitschké P, Guerrera IC, Bole C, Izmiryan A, Puig-Lombardi ME, Fox J, Kirma J, Zhang H, Gu Y, Bogle R, Boniface K, Seneschal J, Seabra L, Lepelley A, Frémond ML, Bondurand N, Jouanguy E, Modlin RL, Casanova JL, Di Domizio J, Gilliet M, Sbidian E, Battistella M, Mahé E, Guégan S, Tsoi LC, Richette P, Claudepierre P, Rigolet A, Giannesini C, Costanzo A, Duffy D, Rosenberg BR, Sathishkumar D, Bourrat E, Chang CH, Hovnanian A, Gudjonsson JE, Crow YJ, Bachelez H. ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype. J Exp Med. 2026 Sep 7;223(9):e20260054. doi: 10.1084/jem.20260054. Epub 2026 Jul 9. PMID: 42424135.

Tags: Dermatology, Publications

Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis

Armstrong AW, Ameen A, Ferrucci S, Pereyra-Rodríguez JJ, Cork MJ, Rubin C, Jarell A, Narcisi A, Becherel PA, Beecker J, Festini T, Vittrup I, Vinther[...]

Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a focused narrative review

Armstrong AW, Strober BE, Liu CM, Cather JC, Merola JF, Lebwohl MG. Effectiveness of brodalumab in biologic-experienced adults with moderate to severe plaque psoriasis: a[...]

Microporous Annealed Particle Wound Matrix for Post-Mohs Defects: A Randomized Controlled Multicenter First-In-Human Study

Hau JT, Martin SJ, Roosa CA, Deshayes S, Hanke CW. Microporous Annealed Particle Wound Matrix for Post-Mohs Defects: A Randomized Controlled Multicenter First-In-Human Study. Dermatol[...]